

ABSTRACT

A novel bone-pathobolism treating agent is provided.

A bone-pathobolism treating agent comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), its homologs, and its variants and a polysaccharide or its derivatives. As the polysaccharide or its derivatives, heparin, dextran sulfate and the like can be used.

A bone-pathobolism treating agent is provided which has excellent therapeutic effect on bone-pathobolism such as osteoporosis, hypercalcemia, or chronic articular rheumatism and persistence of the activity. The agent is useful as a medicine.